Delayed-Onset High Altitude Pulmonary Edema: A Case Report

Bhattarai, Anjan; Acharya, Suman; Yadav, Jayant Kumar; Wilkes, Matt

doi:10.1016/j.wem.2018.11.002

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aggravation of the disease further leads to fatal diseases such as HAPE [38,57]. HAPE is a kind of noncardiogenic pulmonary edema that usually occurs at altitudes of more than 2500 metres [58]. This is consistent with the results of this study.…”

Section: Discussionsupporting

confidence: 92%

Analysis of the mountain sickness of tourists in China from 2015-2017

Xie

2020

Preprint

View full text Add to dashboard Cite

Background: Mountain sickness significantly affects tourists who travel in plateau areas. Most studies have researched patients, climbers and local residents to analyse the identification, causes, symptoms and effects of mountain sickness, and only a few have assessed tourists.Methods: This study used the Jiangtai Insurance Broker, an exemplary underwriting platform for travel agency liability insurance in China, as the data acquisition platform to analyse tourist altitude sickness from an epidemiological perspective. The chi-square test was used to test the distribution of mountain sickness diseases and symptoms among different genders and ages. A geographic information system (GIS) was used to generate a spatial distribution map of tourist mountain sickness.Results: From 2015 to 2017, there were 361 cases of tourist mountain sickness, which were distributed in 4 altitudinal classes. The incidence of mountain sickness was higher in women than in men. Tourists aged 40-69 years were the main group of patients. Acute mountain sickness (AMS) and high-altitude pulmonary edema (HAPE) were the main high-altitude diseases and mainly occurred in the 2nd and 3rd class altitude regions. Hypoxia, dizziness, headache and chest tightness were the main symptoms of mountain sickness. Spring, summer and autumn were the peak seasons for the onset of mountain sickness. Mountain sickness cases were concentrated in a few cities in Western China.Conclusion: This study analysed the genders and characteristics of the main tourist population that suffered from mountain sickness and investigated the diseases and the temporal and spatial regularity of disease from an epidemiological perspective. The research showed that the onset of mountain sickness was related to the individual physique and age of tourists, speed of entering the plateau, season and altitude. This study is significant as a reference for the risk assessment of tourists visiting plateau areas.

show abstract

Section: Discussionsupporting

confidence: 92%

Analysis of the mountain sickness of tourists in China from 2015-2017

Xie

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The average time of onset for HAPE in this study was approximately 4 days after arriving at high-altitude areas, which is consistent with the 2–5 days reported in the previous literature [ 23 ]. The latest onset of symptoms in our study occurred on the tenth day after entering the high-altitude area, which is later than what has been reported in the literature [ 24 ]. This difference may be related to variations in factors such as oxygen supply facilities, level of exertion, and individual susceptibility.…”

Section: Discussioncontrasting

confidence: 44%

Effect of furosemide in the treatment of high-altitude pulmonary edema

Tenzing,

Suolang,

Gesang

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Background High-altitude pulmonary edema (HAPE) refers to the onset of breathlessness, cough, and fever at rest after arriving at high altitudes. It is a life-threatening illness caused by rapid ascent to high altitudes. Furosemide is controversial in HAPE treatment but is routinely used in China. Further research is needed to assess its efficacy and impact on HAPE management and prognosis. The aim of this study is to determine the effectiveness of furosemide for HAPE. Methods A retrospective was conducted to analysis of patients with HAPE admitted to the People’s Hospital of Shigatse City from January 2018 to September 2023. Patients were divided into furosemide group and non-furosemide group for further analysis. Clinical variables including demographic information, comorbidities, vital signs, inflammatory markers, biochemical analysis, CT severity score and prognostic indicators were collected. Results A total of 273 patients were enrolled, with 209 patients in the furosemide group and 64 patients in the non-furosemide group. The furosemide group showed a significantly decrease in CT severity scores compared to the non-furosemide group. Subgroup analysis showed that the longer the duration of furosemide use, the more pronounced the improvement in lung CT severity scores. But there were no significant differences in length of hospital stay and in-hospital mortality between the two groups. Conclusion Furosemide helps alleviate pulmonary edema in HAPE patients, but further research is needed to clarify its impact on prognosis.

show abstract

“…The present case describes the occurrence of HAPE in a previously healthy patient who traveled from Connecticut, USA (mean elevation of 152 m above sea level) to Bogotá, Colombia (mean elevation of 2640 m above sea level). This would be among the first cases reported to our knowledge of HAPE presenting below 3000 m, with an absolute elevation of 2488 m. Walker C. et al [ 11 ] describe a case of HAPE in a patient in Ohio, USA, with a recent elevation of approximately 2926 m after a trip to Breckenridge, USA; while, other reported cases worldwide are described in heights above 3000 m [ 4 , 8 , [11] , [12] , [13] , [14] ].…”

Section: Discussionmentioning

confidence: 93%

“…HAPE is a potentially lethal condition that tends to occur two to five days after the ascent of heights greater than 2500–3000 m [ [1] , [2] , [3] ]. Many factors contribute to the development of this condition such as oxygen decrease, rate of ascent, strenuous exercise, cold weather, recent acute respiratory infections, and male sex [ [2] , [3] , [4] ]. Genetic factors have also been described, such as missense mutations in the Janus kinase 2 gen (jak2) and in the p1b1 cytochrome genes; and a deletion in the histidine rich glycoprotein (HRG), which increases the probability of presenting HAPE at young ages [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%